EDW
16.11.2022 08:37:40 CET | Business Wire | Press release
European DataWarehouse (EDW), along with Hypoport BV, Università Ca’ Foscari Venezia, Woonnu B.V., Unión de Créditos Inmobiliarios S.A. Establecimiento Financiero de Crédito and Dexai-Etica Artificiale, is pleased to announce the launch of the “Engage for ESG Activation Investments” (ENGAGE) project, which has received a grant by the European Climate, Infrastructure and Environment Executive Agency (CINEA) under the LIFE programme.
ENGAGE aims to jointly create a future-proof data and innovative funding framework for energy efficient mortgage and renovation financing, making sustainable energy investments more attractive to private investors and aligning them with the EU’s sustainable finance policy.
Project coordinator and EDW Head of Business Development and Regulatory Affairs, Marco Angheben says, “European DataWarehouse is excited to be leading this consortium which will bring together the necessary technical and jurisdictional diversity required for successful project implementation and a positive impact on the sustainable finance market.”
“We are excited to be paving the way for strong growth in energy efficiency investments across Europe,” adds Hypoport’s Vincent Mahieu. “The regulatory and technical infrastructure must be robust for all market participants, including consumers, to reach its tremendous potential. We are proud and encouraged to receive funding from CINEA.”
Over a three-year period, the ENGAGE team will work on developing a standardised energy efficiency data disclosure template for mortgage loans in line with the most relevant European regulations. The template will be operationalised through the Green Investment Portal.
The ENGAGE framework for energy efficient mortgages and renovations will create transparency through the translation and application of the relevant sections of the EU Taxonomy (and forthcoming EPBD) into the Dutch and Spanish national building and mortgage-lending practices that will ultimately contribute to standardisation of innovative and decarbonisation-targeted capital markets financing transactions.
Project Background
Attracting private investments and stimulating green loan financing is crucial for the EU mission of achieving a zero-emission building stock by 2050. ENGAGE aims to provide a solution to have a single data disclosure format for mortgage funding and regulatory purposes encompassing the most relevant European ESG regulations such as the EU Taxonomy, EU GBS and EPBD. Thereby ENGAGE aims to facilitate a truly new format that facilitates both the banks, regulators and investors by combining existing mortgage disclosure(s) with new (and recently announced) ESG regulations, such as the EU Taxonomy. Creating transparency on definitions and requirements, with respect to the data-needs will allow the Financial Institutions to translate these needs towards the consumer products as well.
Why ENGAGE?
Buildings are responsible for approximately 40% of EU energy consumption and 36% of EU greenhouse gas emissions. Currently in Europe about 75% of existing buildings are qualified as ‘energy inefficient’; yet 85%-95% of today’s buildings will still be in use in 2050. Every year about 1% of buildings undergo an energy efficient renovation1. Home renovations and the financing thereof should increase. Financing the energy efficiency improvement property stock is an important component in realising the greenhouse gas emission reduction objectives. The mortgage market can play a crucial role in providing funding to home renovation programmes aimed at improving the energy performance of the European building stock. The ENGAGE framework for energy efficient mortgages and renovations will create transparency through the translation and application of the relevant sections of the EU Taxonomy (and forthcoming EPBD) into the Dutch and Spanish national building and mortgage-lending practices that will ultimately contribute to standardisation of innovative and decarbonisation-targeted capital markets financing transactions.
DISCLAIMER: Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.
1 https://ec.europa.eu/info/news/focus-energy-efficiency-buildings-2020-feb-17_en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006225/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
